Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic Kidney Disease (CKD) Hemodialysis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    61 result(s) found for: Chronic Kidney Disease (CKD) Hemodialysis. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-000995-13 Sponsor Protocol Number: DECODE-CKD Start Date*: 2022-01-26
    Sponsor Name:Department of Cardiology, Herlev and Gentofte hospital
    Full Title: A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD)
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-022994-32 Sponsor Protocol Number: 34009 Start Date*: 2011-06-24
    Sponsor Name:UMC Utrecht
    Full Title: Effect of N-acetylcysteine on hydrogen sulfide in chronic kidney disease
    Medical condition: Chronic kidney disease End stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064848 Chronic kidney disease LLT
    12.1 10014646 End stage renal disease (ESRD) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001520-18 Sponsor Protocol Number: NL76839.042.21 Start Date*: 2021-04-09
    Sponsor Name:RECOVAC consortium
    Full Title: Long term efficacy and safety of SARS-CoV-2 vaccination in Dutch patients with chronic kidney disease stage G4-G5, on dialysis or after kidney transplantation
    Medical condition: COVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccin...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 10042613 - Surgical and medical procedures 10084464 COVID-19 immunization LLT
    23.1 10042613 - Surgical and medical procedures 10084465 COVID-19 vaccination LLT
    23.1 100000004848 10084508 COVID-19 antibody test LLT
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 10042613 - Surgical and medical procedures 10084462 SARS-CoV-2 vaccination LLT
    23.0 10042613 - Surgical and medical procedures 10084463 SARS-CoV-2 immunisation LLT
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    20.0 10042613 - Surgical and medical procedures 10061105 Dialysis PT
    20.0 10042613 - Surgical and medical procedures 10018875 Haemodialysis PT
    20.0 10042613 - Surgical and medical procedures 10034660 Peritoneal dialysis PT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    23.1 10038359 - Renal and urinary disorders 10076412 Chronic kidney disease stage 5 LLT
    23.1 10038359 - Renal and urinary disorders 10076411 Chronic kidney disease stage 4 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-005057-31 Sponsor Protocol Number: APO-EPO-02 Start Date*: 2013-02-14
    Sponsor Name:APOTEX Inc.
    Full Title: A phase III, randomized, assessor-blinded, active-controlled, multicenter study of the efficacy and safety of APO-EPO as compared to Procrit® when given subcutaneously to patients with anemia of ch...
    Medical condition: Anemia and chronic kidney disease stage 5D (patients on stable hemodialysis)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) SK (Completed) BG (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-000765-37 Sponsor Protocol Number: P-CKD-01 Start Date*: 2007-05-10
    Sponsor Name:Pharmacosmos A/S
    Full Title: A non-comparative open-label study of Iron Oligosaccharide in Chronic Kidney Disease patients with a need for parenteral iron
    Medical condition: Patients with Chronic kidney disease who are in pre-dialysis or undergoing dialysis (either Peritoneal Dialysis or Haemodialysis), who may be treated with erythropoeisis stimulating agents and have...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002062 Anaemia iron deficiency LLT
    9.1 10018875 Haemodialysis LLT
    9.1 10061105 Dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-006320-20 Sponsor Protocol Number: CT.SVL.PD.10.001 Start Date*: 2012-05-17
    Sponsor Name:Synthon BV
    Full Title: A multicenter, randomized, double-blind, multiple dose, crossover study to evaluate the safety and equivalence of serum phosphate control of a new sevelamer carbonate tablet formulation in compari...
    Medical condition: Evaluation of the safety and equivalence of serum phosphate control of a sevelamer carbonate tablet formulation in comparison with Renvela® in chronic kidney disease patients on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020712 Hyperphosphatemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-005160-34 Sponsor Protocol Number: MV-1-2017 Start Date*: 2017-04-21
    Sponsor Name:Universitetsklinikken for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro, Hospitalsenheden Vest
    Full Title: 18F-NaF PET/CT in combination with biomarkers for the classification of renal osteodystrophy in chronic kidney disease
    Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially renal osteodystofi.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10065404 Combined positron emission tomogram and computerised tomogram LLT
    20.0 10022891 - Investigations 10022891 Investigations SOC
    20.0 100000004865 10066622 Chronic hemodialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004136-30 Sponsor Protocol Number: 20130213 Start Date*: 2014-03-05
    Sponsor Name:KAI Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
    Medical condition: Secondary hyperparathyroidism in subjects with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    18.0 10014698 - Endocrine disorders 10020706 Hyperparathyroidism NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) IT (Completed) BE (Completed) AT (Completed) ES (Completed) PT (Completed) LT (Completed) PL (Completed) CZ (Completed) DK (Completed) LV (Completed) DE (Completed) GR (Completed) HU (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000868-30 Sponsor Protocol Number: NL76215.042.20 Start Date*: 2021-02-17
    Sponsor Name:RECOVAC consortium
    Full Title: The immune-response and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant
    Medical condition: COVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccin...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023438 Kidney transplant LLT
    20.0 10042613 - Surgical and medical procedures 10061105 Dialysis PT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    23.1 10042613 - Surgical and medical procedures 10084465 COVID-19 vaccination LLT
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 10042613 - Surgical and medical procedures 10084464 COVID-19 immunization LLT
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    23.0 10042613 - Surgical and medical procedures 10084462 SARS-CoV-2 vaccination LLT
    23.0 10042613 - Surgical and medical procedures 10084463 SARS-CoV-2 immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002610-13 Sponsor Protocol Number: M11-612 Start Date*: 2013-12-06
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3, Open-Label, Multicenter Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 with Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hem...
    Medical condition: - Stage 5 chronic kidney disease - Secondary to hyperparathyroidism
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005092-33 Sponsor Protocol Number: M10-221 Start Date*: 2008-06-10
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: The PRIMO II Study: Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5
    Medical condition: Stage 5 Chronic Kidney Disease (CKD) in subjects receiving hemodialysis who have left ventricular hypertrophy (LVH).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    9.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Prematurely Ended) CZ (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000192-33 Sponsor Protocol Number: 20120360 Start Date*: 2013-07-12
    Sponsor Name:KAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)
    Full Title: A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of A...
    Medical condition: Chronic Kidney Disease Secondary Hyperparathyroidism (SHPT)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004857 10064848 Chronic kidney disease LLT
    17.1 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed) IT (Completed) CZ (Completed) LV (Completed) SE (Completed) AT (Completed) BE (Completed) ES (Completed) EE (Completed) DE (Completed) GR (Completed) LT (Completed) DK (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010904-27 Sponsor Protocol Number: MK-2578-003 Start Date*: 2009-09-07
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients With Chronic Kidney Disease...
    Medical condition: Anemia in patient with Kidney Disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009120 Chronic renal failure anaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007758-70 Sponsor Protocol Number: NH19707 Start Date*: 2008-06-24
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An open-label multi-center, multiple dose study to determine the optimum starting dose of intravenous MIRCERA® for maintenance treatment of anemia in pediatric patients with chronic kidney disease ...
    Medical condition: Anemia associated with chronic kidney disease in pediatric patients (CKD) on hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10058124 Nephrogenic anemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) FR (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002096-26 Sponsor Protocol Number: MV-3-2017 Start Date*: 2017-08-24
    Sponsor Name:Universitetsklinik for Nyresygdomme og Blodtryksforhøjelse, Regionshospitalet Holstebro; Hospitalsenheden Vest
    Full Title: Investigate the differences between treating Chronic Kidney Disease - Mineral and Bone Disorder with an iron-containing phosphate binder or a calcium-containing phosphate binder in dialysis patients.
    Medical condition: Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD), especially bone metabolism and blood vessel calcification
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10027425 Metabolic bone disorders HLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10078095 Chronic kidney disease-mineral and bone disorder PT
    20.0 100000004869 10012347 Dependence on renal dialysis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002682-19 Sponsor Protocol Number: PHI113633 Start Date*: 2013-12-20
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A Phase 2B, randomized, blinded, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the dose response relationship of GSK1278863 over the first 4 weeks of treatment and...
    Medical condition: Anemia associated with chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) CZ (Completed) GB (Completed) DK (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-001824-36 Sponsor Protocol Number: 201201 Start Date*: 2012-07-12
    Sponsor Name:Medical University of Vienna, Department of Medicine III, Division of Nephrology und Dialysis
    Full Title: ORAL SODIUM BICARBONATE SUPPLEMENTATION IN PATIENTS WITH CHRONIC METABOLIC ACIDOSIS AND CHRONIC KIDNEY DISEASE
    Medical condition: Patients classified to have chronic kidney disease of stage 3 and 4 and chronic metabolic acidosis (venous serum HCO3- of <21mml/L on 2 separate measurements at least 1 day apart) should be include...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10027433 - Metabolism and nutrition disorders 10066569 Chronic acidosis LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004472-21 Sponsor Protocol Number: PCS_03_16 Start Date*: 2017-08-31
    Sponsor Name:Pieris Pharmaceuticals GmbH
    Full Title: Phase IIa study to evaluate the safety, pharmacokinetics, and pharmacodynamics of repeated administrations over 4 weeks of the hepcidin antagonist PRS-080#022-DP in anemic chronic kidney disease pa...
    Medical condition: Anemia of chronic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10054310 Anemia of chronic disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2016-000541-31 Sponsor Protocol Number: 200807 Start Date*: 2016-12-02
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evalu...
    Medical condition: Anemia associated with chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) DE (Completed) SE (Completed) PT (Completed) ES (Completed) NL (Completed) AT (Completed) GR (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002411-34 Sponsor Protocol Number: 20140315 Start Date*: 2019-01-28
    Sponsor Name:Amgen Inc.
    Full Title: Phase 3, Randomized, Open-label, Controlled, Multiple-Dose, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Etelcalcetide in Pediatric Subjects 28 days to < 18 Years of age With Sec...
    Medical condition: Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020708 Hyperparathyroidism secondary PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 09:39:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA